Gene therapy returns to centre stage
The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Abstract
Recent clinical trials of gene therapy have shown remarkable therapeutic benefits and an excellent safety record. They provide evidence for the long-sought promise of gene therapy to deliver 'cures' for some otherwise terminal or severely disabling conditions. Behind these advances lie improved vector designs that enable the safe delivery of therapeutic genes to specific cells. Technologies for editing genes and correcting inherited mutations, the engagement of stem cells to regenerate tissues and the effective exploitation of powerful immune responses to fight cancer are also contributing to the revitalization of gene therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Allogeneic hematopoietic stem and progenitor cell (HSPC) transplantation (allo-HSCT) can provide a one-time and life-long cure for patients with serious genetic hematological diseases such as primary immunodeficiencies20 and hemoglobinopathies21,22, if a suitable immunologically matched donor can be found23.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [23]
In the citing paper
“Although insertional mutagenesis risk has been reduced by improved vector design19, the development of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) at 3–5.5 years post-transplantation in 2 of 47 patients who had undergone GT for SCD20–23 has generated renewed concerns.”
From Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease (2023) · cites this paper as [19]
In the citing paper
“Gene therapy with autologous hematopoietic stem cells has been investigated as an alternative to allogeneic hematopoietic stem-cell transplantation.11–13”
From Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy (2017) · cites this paper as [12]
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
Hematopoietic Stem-Cell Transplantation
Copelan, E. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052638 · Cited by 2,522
Research works printed but not linked: 1
- Baxter. Baxalta reports continued progress on phase 1/2 clinical trial of BAX335, investigational gene therapy treatment for hemophilia B. Baxter http://www.baxter.com/news-media/newsroom/press-releases/2015/06_24_15_bax335.page (2015).
Cited by
Items 801–900 of 1,000
Gu, J., Liu, F., Li, L., & Mao, J. (2025) · Biomedicines · doi:10.3390/biomedicines13020523 · Cited by 7
“The commonly used vectors for gene delivery include lentivirus, adenovirus, AAV, and plasmid DNA, with selection criteria depending on factors such as gene size, duration of expression, and safety profile [90,91].”
Innovative gene therapy strategies for tackling obesity
Sheikh‐Hosseini, M., Moarefzadeh, M., Alsaedi, A. A., Amshawee, A. M., Al-Mozani, S. K., Abed, A. Y., Neissi, M., & Roudsari, P. P. (2025) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-025-00686-8 · Cited by 7
“Oncolytic viruses have been used to target cancer cells, and adenoviral vectors of simian origin are being explored for their potential in immune response induction through vaccination [64].”
Chendeb, M., Schneider, R., Davidson, I., & Fadloun, A. (2017) · Oncotarget · doi:10.18632/oncotarget.16013 · Cited by 6
Translational Medicine Strategies in Drug Development for Neurodevelopmental Disorders
Srivastava, S., Şahin, M., & Prock, L. A. (2019) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-803161-2.00022-9 · Cited by 9
An acoustic field-based conformal transfection system for improving the gene delivery efficiency
Xie, L., Wang, J., Zhao, S., Lai, M. L., Jiang, T., & Yan, F. (2021) · Biomaterials Science · doi:10.1039/d1bm00251a · Cited by 6
Hosmani, J., Mushtaq, S., Abullais, S. S., Almubarak, H. M., Assiri, K. I., Testarelli, L., Mazzoni, A., & Patil, S. (2021) · Medicina · doi:10.3390/medicina57050438 · Cited by 8
Immunotherapy and CRISPR Cas Systems: Potential Cure of COVID-19?
He, X., & Zeng, X. X. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s347297 · Cited by 8
“The average size of Cas13d is 930 aa allowing CasRx effector domain fusions to be paired with a CRISPR array encoding multiple guide RNAs can still fit into the adeno-associated virus delivery vehicle for in vivo delivery.(168) Cas13d could block expression of the viral gene by cleavage of the specific RNA sequence of…”
BackgroundMohanlal, R. W., Qiu, Y., Zheng, M., Mirkou, A., Sridharan, K., & Keir, C. H. (2016) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-016-0229-9 · Cited by 6
“The author contends that, in any given trial, the actual risk of genotoxicity is difficult to establish because of the low number of patients treated, the longer follow-up period needed, and possibility of the disease itself increasing the risk [31].”
BackgroundGene-modified, cell-based therapies—an overview
Powell, A. B., Williams, K., & Cruz, C. C. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2016.09.001 · Cited by 7
Lipid-based nanocarriers for cancer gene therapy
Shah, M. R., Imran, M. A., & Ullah, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-52729-3.00009-3 · Cited by 5
Virus-Based Therapeutic Approaches
Marintcheva, B. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-810514-6.00009-x · Cited by 6
Recent Advances in Therapeutic Genome Editing in China
Yang, Y., Wang, Q., Li, Q., Men, K., He, Z., Deng, H., Ji, W., & Wei, Y. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.210 · Cited by 6
Sundaram, D. N. M., Vij, M., Pandey, T., Natarajan, P., Sharma, R., Mishra, S., & Ganguli, M. (2018) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.8b00069 · Cited by 6
Group I Intron-Based Therapeutics Through Trans-Splicing Reaction
Lee, C. H., Han, S. R., & Lee, S. (2018) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2018.07.001 · Cited by 7
Yan, F., Wu, J.-S., Liu, Z., Yu, H., Wang, Y., Zhang, W., & Ding, D. (2018) · Nanoscale Research Letters · doi:10.1186/s11671-018-2820-y · Cited by 6
Which Nanobasics Should Be Taught in Medical Schools?
Sunshine, J. C., & Paller, A. S. (2019) · The AMA Journal of Ethic · doi:10.1001/amajethics.2019.337 · Cited by 6
Mesenchymal Stem Cells: A New Generation of Therapeutic Agents as Vehicles in Gene Therapy
Gharbavi, M., Sharafi, A., & Ghanbarzadeh, S. (2020) · Current Gene Therapy · doi:10.2174/1566523220666200607190339 · Cited by 6
Engineering precision therapies: lessons and motivations from the clinic
Xie, M., Viviani, M., & Fussenegger, M. (2020) · Synthetic Biology · doi:10.1093/synbio/ysaa024 · Cited by 11
Lipoic Acid-Modified Oligoethyleneimine-Mediated miR-34a Delivery to Achieve the Anti-Tumor Efficacy
Huang, Y. S., Wang, L., Chen, Y., Han, H., & Li, Q. (2021) · Molecules · doi:10.3390/molecules26164827 · Cited by 6
“Except for these routes, gene therapy has been widely investigated in which exogenous nucleic acids were used as therapeutics to suppress the oncogenes and trigger the anti-proliferation and anti-migration effects of tumors [4,5].”
BackgroundGene delivery into cells and tissues
Nelson, C. E., Duvall, C. L., Prokop, A., Gersbach, C. A., & Davidson, J. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818422-6.00030-7 · Cited by 9
Nonviral vector system for cancer immunogene therapy
Nie, W., Chen, J., Wang, B., & Gao, X. (2022) · MedComm – Biomaterials and Applications · doi:10.1002/mba2.10 · Cited by 7
Diener, Y., Bosio, A., & Bissels, U. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.08.004 · Cited by 6
Chen, P., Liu, Y., Zhao, J., Pang, X., Zhang, P., Hou, X., Chen, P., He, C., Wang, Z., & Chen, Z.-Y. (2018) · Biomaterials Science · doi:10.1039/c7bm01143a · Cited by 6
Xu, Y., Wang, X., Guo, B., Wang, D., Kalvakolanu, D. V., Chen, X., Tang, J., Zhang, L., & Yang, Q. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.134 · Cited by 5
Minh, A. D., Tran, M. Y., & Kamen, A. (2019) · Methods in molecular biology · doi:10.1007/978-1-0716-0146-4_6 · Cited by 6
Ultrasound-assisted magnetic nanoparticle-based gene delivery
Zhang, W., Abdelrasoul, G. N., Savchenko, O., Abdrabou, A., Wang, Z., & Chen, J. (2020) · PLoS ONE · doi:10.1371/journal.pone.0239633 · Cited by 6
Enhancing therapeutic efficacy of in vivo platelet-targeted gene therapy in hemophilia A mice.
Wang, X., Fu, R. Y., Li, C., Chen, C., Firrman, J., Konkle, B. A., Zhang, J., Li, L., Xiao, W., Poncz, M., et al. (2020) · PubMed Central · doi:10.1182/bloodadvances.2020002479 · Cited by 10
Gene editing for advanced therapies: Governance, policy and society
Garden, H., & Winickoff, D. E. (2018) · OECD science, technology and industry working papers · doi:10.1787/8d39d84e-en · Cited by 14
“Some types of gene editing applications for health are considered “acceptable” in society today, and others – subject to certain limitations and/ or stringent regulatory safeguards – might be considered “unacceptable” at this time (Baltimore et al., 2015[11]; Naldini, 2015[55]; Lander, 2015[34]).”
BackgroundModeling integration site data for safety assessment with MELISSA
Lin, T., Ceoldo, G., House, K. D., Welty, M., Dang, T. T., Klatt, D., Brendel, C., Murphy, M. P., Cornetta, K. G., & Pellin, D. (2025) · Nature Communications · doi:10.1038/s41467-025-63017-w · Cited by 6
“We introduce MELISSA, a regression-based statistical framework for analyzing Integration Site (IS) data to assess insertional mutagenesis risk, by estimating and comparing gene-speci fi c integration rates and their impact on clone fi tness.”
Mohammadi, R., Sakic, I., Jain, A., Mathur, P., Weiß, T., deMello, A. J., Stavrakis, S., & Asghari, M. H. (2025) · Small · doi:10.1002/smll.202507981 · Cited by 5
Ren, J., & Stroncek, D. F. (2016) · Blood · doi:10.1182/blood-2016-09-736983 · Cited by 5
Fu, J., Zheng, H., Ou, Y., Yang, G., Chen, Z., & Yuan, G. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.008 · Cited by 5
“10 Adeno-associated virus (AAV) is the mostly used viral vector for gene therapy.”
Target search of a polymer with an active head
Sahoo, R., Saini, A., & Chakrabarti, R. (2025) · Soft Matter · doi:10.1039/d5sm00281h · Cited by 5
Li, Y., Sun, X., Yang, Y., Wei, X., Liu, Y., Jia, H., & Liu, W. (2021) · Materialia · doi:10.1016/j.mtla.2021.101115 · Cited by 5
Prenatal Gene Therapy for Metabolic Disorders
Coons, B. E., & Peranteau, W. H. (2021) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000662 · Cited by 7
Jiang, Q., Guan, S., Zhang, Y., Sun, Y., & Jiang, X. (2022) · International Journal of Polymeric Materials · doi:10.1080/00914037.2022.2029438 · Cited by 5
Administration and detection of gene therapy in horses: A systematic review
Haughan, J. E., Ortved, K. F., & Robinson, M. A. (2022) · Drug Testing and Analysis · doi:10.1002/dta.3394 · Cited by 6
Cui, L., Kudsiova, L., Campbell, F., Barlow, D. J., Hailes, H. C., Tabor, A. B., & Lawrence, M. J. (2023) · Biomaterials Science · doi:10.1039/d2bm01905a · Cited by 5
Barriocanal‐Casado, E., Cueto‐Ureña, C., Benabdellah, K., Gutiérrez-Guerrero, A., Cobo, M., Hidalgo‐Gutiérrez, A., Rodríguez‐Sevilla, J. J., Martín, F., & López, L. C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158344 · Cited by 6
Gurusinghe, S., Hilbert, B. J., Trope, G. D., Wang, L., Bandara, N., & Strappe, P. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25773 · Cited by 5
“As a cell reprogramming tool lentiviral vectors offer great promise for the future, with human trials underway highlighting their safety [Naldini, 2015].”
BackgroundFuture Aspects of Clinical Osteoarthritis Therapies in the Continuum of Translational Research
Schrenker, S., Gao, L., Cucchiarini, M., & Madry, H. (2019) · Zeitschrift für Orthopädie und Unfallchirurgie · doi:10.1055/a-0806-8225 · Cited by 7
“They are essentially based on improved vector design, that permits safe clinical presentation of therapeutic genes for specific diseases [91].”
BackgroundCalcium Phosphate Nanoparticle-Based Systems for Therapeutic Delivery
Piao, Y., Bei, H., Tam, A., Yang, Y., Zhang, Q., Yang, M., & Zhao, X. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815341-3.00006-7 · Cited by 6
Bulk and Microfluidic Synthesis of Stealth and Cationic Liposomes for Gene Delivery Applications
de la Torre, L. G., Pessoa, A. C. S. N., de Carvalho, B. G., Taketa, T. B., Eş, İ., & Perli, G. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0872-2_14 · Cited by 5
Khan, A. S., Amara, P. S., & Morse, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815379-6.00008-8 · Cited by 9
An Intelligent Nanomachine Guided by DNAzyme Logic System for Precise Chemodynamic Therapy
Wang, Z., Yang, J., Qin, G., Zhao, C., Ren, J., & Qu, X. (2022) · Angewandte Chemie · doi:10.1002/ange.202204291 · Cited by 6
Nam, J.-S., Lee, J.-E., Lee, K.-H., Yang, Y., Kim, S.-H., Bae, G., Noh, H., & Lim, K. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.11.001 · Cited by 5
Farajifard, H., Zavvar, M., Rajaei, T., Noorbakhsh, F., Nikougoftar‐Zarif, M., Azadmanesh, K., Kompani, F., & Rezaei, N. (2018) · European Cytokine Network · doi:10.1684/ecn.2018.0419 · Cited by 5
“Number and heterogeneity of isease-causing genetic defects, together with specific ells/tissues affected by the genetic abnormalities, have een two important determinants in the success of gene herapy projects [17].”
BackgroundZhang, J.-H., He, X., Xiao, Y., Zhang, J., Wu, X., & Yu, X. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c00118 · Cited by 5
Czuba‐Wojnilowicz, E., Miellet, S., Glab, A., Viventi, S., Cavalieri, F., Cortez‐Jugo, C., Dottori, M., & Caruso, F. (2020) · Biomacromolecules · doi:10.1021/acs.biomac.0c00626 · Cited by 5
Kim, J. S., Kim, M. W., Jeong, H. Y., Kang, S. J., Park, S. I., Lee, Y. K., Kim, H. S., Kim, K. S., & Park, Y. S. (2016) · The Journal of Gene Medicine · doi:10.1002/jgm.2884 · Cited by 5
“Gene therapy has regained importance because of recent successful clinical trials reporting remarkable therapeutic benefits [1].”
BackgroundRecent alternative approaches of vascular drug-eluting stents
Han, C., Park, K., & Joung, Y. K. (2017) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-017-0378-9 · Cited by 5
“2014), has ability to regulate cell function, which allows it to be widely studied in the regeneration field (Naldini 2015; Rios et al. 2011).”
BackgroundApplications of Virus Vector–Mediated Gene Therapy in China
Lin, Q., Deng-gao, W., Zhang, Z., & Liu, D. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.238 · Cited by 5
“5 In China, virus vector–mediated gene therapy research and clinical trials have also been widely conducted for many diseases, particularly complex diseases.”
Bošnjak, M., Kamenšek, U., Serša, G., Stolfa, D., Lavrenčak, J., & Čemažar, M. (2017) · The Journal of Membrane Biology · doi:10.1007/s00232-017-9960-3 · Cited by 5
Human‐Machine Interaction in Leveraging the Concept of Telemedicine
Israni, D. K., & Chawla, N. S. (2023) · Wiley eBooks · doi:10.1002/9781394200344.ch8 · Cited by 9
Enzyme Replacement Therapy & Other Therapeutic Frontiers in Infantile Metabolic Disorders
Choi, H., Sriram, A., Sargiotto, C., & Fajardo, V. M. (2025) · NeoReviews · doi:10.1542/neo.26-12-081 · Cited by 4
Synthetic Biology Industry: Biosafety Risks to Workers
Murashov, V. V., Howard, J., & Schulte, P. A. (2019) · Risk, systems and decisions · doi:10.1007/978-3-030-27264-7_8 · Cited by 4
Characteristic time for the end monomers of a spherically confined polymer to find a nano-pore
Hoseinpoor, S. M., Nikoofard, N., & Ha, B. (2021) · The Journal of Chemical Physics · doi:10.1063/5.0040551 · Cited by 4
WAC, a novel GBM tumor suppressor, induces GBM cell apoptosis and promotes autophagy
Wang, Y., Zhang, S., Sun, Q., Yuan, F., Zhao, L., Ye, Z., Li, Y. H., Wang, R., Jiang, H., Hu, P., et al. (2021) · Medical Oncology · doi:10.1007/s12032-021-01580-0 · Cited by 4
Classifications, synthesis and applications of biodegradable pseudo-proteins: a review
Xue, Y., Liu, Y., Zhang, X., Sun, M., Chen, Y., & Yang, F. (2023) · Macromolecular Research · doi:10.1007/s13233-023-00217-7 · Cited by 6
Seclén, E., Jang, J. C., Lawal, A. O., Pulicani, S., Boyne, A. R., Tkach, D., Juillerat, A., Duchateau, P. N., & Valton, J. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.04.001 · Cited by 4
Zhang, X., Xu, D.-Z., Zhang, Z., Ren, Z.-X., Wu, J.-R., Xu, Y.-J., Lu, Z., Liu, R., & Liu, Y. (2024) · Polymer Chemistry · doi:10.1039/d4py00610k · Cited by 5
Engineering CRISPR for emerging therapeutic applications
Sun, X., & Liu, Z. (2024) · EngMedicine · doi:10.1016/j.engmed.2024.100035 · Cited by 4
Prader-Willi syndrome: Genetics, clinical symptoms, and model systems
Saade, M., Rike, W. A., Sharma, O., Abu-Akel, A. M., & Stern, S. (2025) · Genomic psychiatry : · doi:10.61373/gp025i.0044 · Cited by 3
Aftermath of the Human Genome Project: an era of struggle and discovery
HAMDOUN, Z., & Ehsan, H. (2017) · TURKISH JOURNAL OF BIOLOGY · doi:10.3906/biy-1609-77 · Cited by 5
Zafir‐Lavie, I., Miari, R., Sherbo, S., Krispel, S., Tal, O., Liran, A., Shatil, T., Badinter, F., Goltsman, H., Shapir, N., et al. (2017) · The Journal of Gene Medicine · doi:10.1002/jgm.2965 · Cited by 4
“Recent progression in gene therapy clinical trials is attributed to the progress made with respect to engineered viral vectors.(38) The use of HDAd vector, which is deleted of all viral coding sequences, has significant advantages, enabling the use of large genes in addition to large cis‐acting elements.”
BackgroundLiu, D., Liu, J., Li, C., Li, W., Wang, W., & Liu, J. (2020) · ACS Omega · doi:10.1021/acsomega.0c00823 · Cited by 4
Chitosan and its derivatives-based dimensional frameworks as carrier for gene delivery
Ashfaq, M., & Ahmad, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821230-1.00014-1 · Cited by 6
Clinical manifestation and current therapeutics in X-juvenile retinoschisis
Yang, Y.-P., Jheng, Y.-C., Chien, Y., Tsai, P.-H., Hwang, D.-K., Weng, C.-C., Huang, Y.-M., Hsu, C.-C., Chou, Y.-B., Chen, S.-J., et al. (2022) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000684 · Cited by 4
Zhu, Y., Lin, M., Hu, W., Wang, J., Zhang, Z., Zhang, K., Yu, B., & Xu, F. (2022) · Angewandte Chemie · doi:10.1002/ange.202200535 · Cited by 4
Chiang, P., Chen, J., Chen, L., & Kuo, M. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.034 · Cited by 4
“17 Gene therapy with viral vectors has been well developed, 18 even the current vaccine for COVID-19 is composed of adenovirus as one of the delivery systems.”
Recent advances in development of nano-carriers for immunogene therapy in various complex disorders.
Shahgordi, S., Oroojalian, F., Hashemi, E., & Hashemi, M. (2022) · PubMed Central · doi:10.22038/ijbms.2022.59718.13245 · Cited by 6
Wu, Z., Huo, X., Yang, T., Liu, K., Wu, T., Feng, Z., Wang, M., Li, F., Jia, J., Zhang, X., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.978533 · Cited by 6
“Actually, tumor-related gene therapy accounts for more than half of the gene therapies entering the clinical stage (8).”
BackgroundWeisshoff, H., Wenzel, K., Schulze-Rothe, S., Nikolenko, H., Davideit, H., Becker, N., Göttel, P., Srivatsa, G. S., Dathe, M., Müller, J., et al. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.04.003 · Cited by 4
Stem Cells as Drug Delivery Vehicles
Kuriakose, A. E., Nguyen, T. P., Noukeu, L. C., Sabhani, M. K., Weidanz, J. A., Le, D., & Nguyen, K. T. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65443-0 · Cited by 4
Gene Therapy Using Genomic DNA
Han, Z. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809813-4.00003-x · Cited by 4
James, D. A., Fradin, M., Pędyczak, A., & Carpick, B. W. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.08.018 · Cited by 4
Characterization of liver specific promoters in a foamy viral vector pMD09
SINGH, A. K., Weber, C., VARSHNEY, A., Gupta, S., Kazim, S. N., Girija, S. M., Rethwilm, A., & Sarin, S. K. (2019) · Acta Virologica · doi:10.4149/av_2019_207 · Cited by 5
“Gene transfer must overcome complex cellular and tissue barriers to deliver new genetic information into the target cell to drive proficient expression of a therapeutic molecule without disrupting essential regulatory mechanisms (Naldini, 2015).”
BackgroundWang, X., He, R., Nian, S., Xiao, B., Wang, Y., Zhang, L., Wang, X., Guo, R., & Lu, Y. F. (2022) · Genes · doi:10.3390/genes13050829 · Cited by 5
“In a review of recent successful stem cell clinical trials, researchers [22] found that HIV-derived, self-inactivated lentiviral vectors are less toxic, make gene transfection more effective, and allow for stable expression, which are desirable in the field of gene therapy.”
BackgroundPerspectivas da terapia gênica
Costanzi-Strauss, E., & Strauss, B. E. (2015) · Revista de Medicina · doi:10.11606/issn.1679-9836.v94i4p211-222 · Cited by 35
Prospects for Foamy Viral Vector Anti-HIV Gene Therapy
Nalla, A. K., & Trobridge, G. D. (2016) · Biomedicines · doi:10.3390/biomedicines4020008 · Cited by 6
“HSC gene therapy has been used to successfully treat monogenic diseases including adenosine deaminase deficient-severe combined immunodeficiency (ADA-SCID), X-linked SCID, X-linked adrenoleukodystrophy and hemophilia B [14].”
MethodIşık, M., Agirre, M., Sesma, J. Z., Puras, G., Mecerreyes, D., Sardón, H., & Pedraz, J. L. (2016) · Journal of Polymer Science Part A Polymer Chemistry · doi:10.1002/pola.28376 · Cited by 4
Sawczuk, I. S., & Wechsler, M. E. (1985) · PubMed Central · Cited by 5
Retroviruses in Human Gene Therapy
Pedersen, F. S., & Mikkelsen, J. G. (2018) · Wiley eBooks · doi:10.1002/9780470015902.a0001002.pub4 · Cited by 4
Reversal of molecular pathology by RNA-targeting Cas9 in a myotonic dystrophy mouse modelPreprint
Batra, R., Nelles, D. A., Krach, F., Thomas, J. D., Snjader, L., Blue, S. M., Aigner, S., Swanson, M. S., & Yeo, G. W.-M. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/184408 · Cited by 5
Radtke, S., Pande, D., Cui, M., Perez, A. M., Chan, Y. Y., Enstrom, M., Schmuck, S., Berger, A., Eunson, T., Adair, J. E., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/850479 · Cited by 4
Effective RNA Delivery with Aggregation-Induced Lipid Backfolding
Wang, G., Wu, M., Ye, J., Xu, Y., Chen, Y., Ju, C., Xu, X., & Zhang, C. (2025) · ACS Nano · doi:10.1021/acsnano.5c07140 · Cited by 3
Gene therapy for disorders of sex development: current applications and future challenges
Peng, W., Zhao, Q., Chen, J., Peng, H., & Jiang, H. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2025.1661127 · Cited by 4
“…to other viral vectors such as AAV and adenovirus, lentiviral vectors offer several distinct advantages, including the ability to transduce non-dividing cells, high transduction ef fi ciency, long-term gene expression, and a relatively large packaging capacity (up to 8 – 10 kb) (Naldini, 2015).”
Yang, X., Luo, W., Wang, Y., Lu, Y., Yu, J., Liu, C., Wang, W., Du, Y., & Yu, R. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102661 · Cited by 6
“Nevertheless, small molecule inhibitors often fail to elicit a sustained response due to the presence of drug resistance and intractable proteins [22], while genetic approaches frequently encounter challenges related to off-target side effects and insufficient transfection efficiency [23].”
Highly efficient expression of DNA-peptide conjugates in growth-arrested cells
Mohamedshah, Z., Chi, C.-C., Tota, E. M., Komor, A. C., & Devaraj, N. K. (2026) · Nature Communications · doi:10.1038/s41467-025-68167-5 · Cited by 4
“1, 2).”
Midena, F., Alessandrini, L., Conci, C., Barcella, M., Gazzo, F., Jacchetti, E., Carsana, E., Benedicenti, F., Vacca, R., della Volpe, L., et al. (2026) · Cell stem cell · doi:10.1016/j.stem.2025.12.016 · Cited by 6
Self-citationSkeletal-muscle-targeted non-viral delivery of full-length DMD mRNA for Duchenne muscular dystrophy
Tian, Y. W., Liu, Y., Tong, Y., Huntoon, K. M., Yang, L., Shi, J., Ma, Y., Dong, S., Jeong, S. D., Estania, A. P., et al. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01689-5 · Cited by 6
Leveraging Vector-Based Gene Disruptions to Enhance CAR T-Cell Effectiveness
de Oliveira, B. C., Bari, S. M. N., & Melenhorst, J. J. (2025) · Cancers · doi:10.3390/cancers17030383 · Cited by 5
Application of Gene Therapy to Oral Diseases
Yamano, S., Inoue, K., & Taguchi, Y. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17070859 · Cited by 6
“Equity and access: Addressing disparities in access to gene therapy treatments, particularly for marginalized and underserved populations, is a critical ethical consideration [135].”
Bordignon, C. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.07.005 · Cited by 5
Gene Editing and CRISPR Therapeutics: Strategies Taught by Cell and Gene Therapy
Ramírez, J. C. (2017) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2017.08.003 · Cited by 3
Genomic Editing—From Human Health to the “Perfect Child”
Iancu, D. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813764-2.00001-5 · Cited by 3
The role of bacteria in the treatment of cancer: A comprehensive review
Khadem, E., Nafari, A., Safarzadeh, A., Jozaei, R. F., Almasian, M., & Elyasi, H. (2020) · Plant Biotechnology Persa · doi:10.29252/pbp.2.1.26 · Cited by 3
Xu, F., Liu, X., Zhang, D., Zhao, F., Fan, Z., Hu, S., Mei, S., Huang, Y., Sun, H., Wei, L., et al. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.292 · Cited by 3
Half-Life Extension Enhances Drug Efficacy in Adeno-Associated Virus Delivered Gene Therapy
Wu, H., Hu, D. M., Li, Q., Wang, C., Zhu, X., Li, W., Chen, B., Ji, P., Huang, K., Huang, A., et al. (2022) · Engineering · doi:10.1016/j.eng.2022.02.009 · Cited by 4
Gene Therapy in Hemophilia: Latest Developments
Sanchez-Lara, P. A., Nathanson, J., & Valentino, L. A. (2022) · Springer eBooks · doi:10.1007/978-3-030-93990-8_18 · Cited by 4
Metadata
- Authors
- Naldini, L.
- Affiliations
- Vita-Salute San Raffaele University (IT)
- Corresponding author
- Naldini, Luigi
- ORCID
- Naldini, Luigi
- Venue
- Nature
- Published
- 2015-10
- Volume
- 526
- Issue
- 7573
- Pages
- 351-360
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1902159756
- Semantic Scholar
- 334eb76dbe52abdfcdb4be9aa772d017378a95d3
- Cited by
- 1,184
- References
- 124
- Citations by year
- 2026: 67 · 2025: 77 · 2024: 59 · 2023: 75 · 2022: 76 · 2021: 99 · 2020: 141 · 2019: 132 · 2018: 182 · 2017: 158 · 2016: 109 · 2015: 7
- FWCI
- 19.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Funders
- Fondazione Telethon
- Ministero della Salute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Keywords
- gene therapy, clinical trials, gene therapy vectors, genome editing, inherited mutations, stem cell therapy, tissue regeneration, cancer immunotherapy, gene therapy safety
- MeSH terms
- Clinical Trials as Topic, Hematopoietic Stem Cells, Humans, Immunotherapy, Liver, Neoplasms, Organ Specificity, T-Lymphocytes, Genetic Therapy, Gene Targeting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.